OpenLB
Open Library of Bioscience
Advanced Search
International urology and nephrology
Mar 23, 2025;

Role and application prospective of non-steroidal MRA in the treatment of diabetic kidney disease.

Yu Sun, Mingzhu Wang
Author Information
  1. Yu Sun: Department of Nephrology, Haining People's Hospital, Haining, 314400, China.
  2. Mingzhu Wang: Department of General Medicine, Haining People's Hospital, Qianjiang West Road, Haining, 314400, Zhejiang, China. szxqwa1128@126.com.
PMID: 40121581 DOI: 10.1007/s11255-025-04456-8

Abstract

Chronic kidney disease (CKD) has diverse etiologies and complex pathogenesis, and is prone to recurrent episodes and prolonged illness. In recent years, the prevalence of CKD has been increasing year by year, and the global prevalence in the general population has reached 14.3%. Diabetic kidney disease (DKD) is a common complication of diabetes mellitus (DM), and about 20-40% of DM patients have combined DKD, which is also the main cause of CKD and end-stage renal disease (ESRD). DM catalyzes CKD in approximately 30-50% of global cases, affecting around 285 million individuals. It primarily triggers diabetic nephropathy (DN), the leading cause of end-stage renal disease worldwide. Research indicates that activation of the mineralocorticoid receptor (MR) plays a role in the onset and progression of DKD. Counteracting MR overactivation offers antioxidative, anti-inflammatory, and anti-fibrotic benefits, thereby ameliorating target organ damage. MR antagonists (MRAs) such as spironolactone and eplerenone have been validated for renal protection. However, their clinical application is hindered by adverse effects including hyperkalemia, gynecomastia in males, erectile dysfunction, and menstrual irregularities in females. Finerenone, a novel non-steroidal MRA, exhibits a unique mechanism of action, binding to MR and inhibiting the recruitment of transcription co-factors involved in gene expression, effectively slowing the progression of diabetic nephropathy (DN). In addition, finerenone demonstrates improved safety and efficacy in treating heart failure and chronic kidney disease. It also plays a significant role in the management of atrial fibrillation and myocardial infarction. This article reviews recent studies on finerenone, summarizing its mechanism of action in treating DN, evidence from clinical trials, adverse reactions, combined use with other inhibitors, and future prospective, aiming to provide insights for the prevention and treatment of DN.

Keywords

Adverse reactions Diabetic nephropathy Finerenone Mechanism of action Mineralocorticoid receptor antagonist

References

  1. Piccirillo F, Liporace P, Nusca A, Nafisio V, Corliano A, Magaro F, Antonelli IR, Ussia GP, Grigioni F (2023) Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality-a comprehensive review. J Cardiovasc Dev Dis 10(6):236 [PMID: 37367401]
  2. Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T (2020) Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet 59(3):359–370 [PMID: 31583611]
  3. Koya D, Anker SD, Ruilope LM, Rossing P, Liu Z, Lee BW, Lee CT, Scott C, Kolkhof P, Lawatscheck R et al (2023) Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: A FIDELIO-DKD post hoc analysis. Am J Nephrol 54(9–10):370–378 [PMID: 37708857]
  4. Gonzalez-Blazquez R, Somoza B, Gil-Ortega M, Martin RM, Ramiro-Cortijo D, Vega-Martin E, Schulz A, Ruilope LM, Kolkhof P, Kreutz R et al (2018) Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front Pharmacol 9:1131 [PMID: 30356804]
  5. Mima A, Lee R, Murakami A, Gotoda H, Akai R, Kidooka S, Nakamoto T, Kido S, Lee S (2023) Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL/min/1.73 m. Metabol Open. 19:100251 [PMID: 37497038]
  6. McGill JB, Agarwal R, Anker SD, Bakris GL, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, Caramori ML, Brinker M et al (2023) Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. Diabetes Obes Metab 25(6):1512–1522 [PMID: 36722675]
  7. Vizcaya D, Kovesdy CP, Reyes A, Pessina E, Pujol P, James G, Oberprieler NG (2023) Characteristics of patients with chronic kidney disease and Type 2 diabetes initiating finerenone in the USA: a multi-database, cross-sectional study. J Comp Eff Res 12(8):e230076 [PMID: 37387399]
  8. Ashjian E, Clarke M, Pogue K (2023) Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am J Health Syst Pharm 80(23):1708–1721 [PMID: 37632460]
  9. Pochopien MT, Cherney D, Folkerts K, Levy P, Millier A, Morris S, Roy-Chaudhury P, Sullivan SD, Mernagh P (2021) FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care 27(20 Suppl):S375–S382 [PMID: 34878755]
  10. Baumstein D (2021) Finerenone and chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 384(11):e42 [PMID: 33730465]
  11. Quist SW, van Schoonhoven AV, Bakker S, Pochopien M, Postma MJ, van Loon J, Paulissen J (2023) Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands. Cardiovasc Diabetol 22(1):328 [PMID: 38017448]
  12. Lerma EV, Wilson DJ (2022) Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Expert Rev Clin Pharmacol 15(5):501–513 [PMID: 35762406]
  13. Ravid JD, Laffin LJ (2022) Effects of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, on cardiovascular disease, chronic kidney disease, and blood pressure. Curr Cardiol Rep 24(10):1251–1259 [PMID: 35925515]
  14. Filippatos G, Anker SD, Bohm M, Gheorghiade M, Kober L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F et al (2016) A randomized controlled study of finerenone vs eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J. 37(27):2105–2114 [PMID: 27130705]
  15. Young MJ, Fuller PJ (2021) Finerenone and chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 384(11):e42 [PMID: 33730468]
  16. Abdelazeem B, Elbadawy MA, Awad AK, Kheiri B, Kunadi A (2022) The carodiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: a meta-analysis of randomized clinical trials. Intractable Rare Dis Res 11(1):31–33 [PMID: 35261849]
  17. Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, Kim SY, Nowack C, Kolkhof P, Shiga T (2016) A Randomized Controlled Study of Finerenone vs. eplerenone in japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease. Circ J. 80(5):1113–1122 [PMID: 27074824]
  18. Barrera-Chimal J, Gerarduzzi C, Rossignol P, Jaisser F (2022) The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clin Sci (Lond) 136(12):1005–1017 [PMID: 35765983]
  19. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Billings LK, Green JB, Koya D, Mosenzon O, Pantalone KM et al (2023) The impact of obesity on cardiovascular and kidney outcomes in patients with chronic kidney disease and type 2 diabetes treated with finerenone: post hoc analysis of the FIDELITY study. Diabetes Obes Metab 25(10):2989–2998 [PMID: 37402696]
  20. Ortiz A, Alcazar AR, Casado EP, Fernandez-Fernandez B, Martinez DF, Mediavilla JD, Michan-Dona A, Soler MJ, Gorriz JL (2023) Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone. Expert Rev Clin Pharmacol 16(6):519–531 [PMID: 37190957]
  21. Mayne KJ, Herrington WG (2022) In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes. Ann Intern Med 175(5):C54
  22. Yang P, Huang T, Xu G (2016) The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: progress and challenges. Metabolism 65(9):1342–1349 [PMID: 27506741]
  23. Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S et al (2023) Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR). Cardiovasc Diabetol 22(1):194 [PMID: 37525257]
  24. Le Billan F, Perrot J, Carceller E, Travers S, Viengchareun S, Kolkhof P, Lombes M, Fagart J (2021) Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells. FASEB J 35(2):e21314 [PMID: 33417258]
  25. Eissing T, Goulooze SC, van den Berg P, van Noort M, Ruppert M, Snelder N, Garmann D, Lippert J, Heinig R, Brinker M et al (2023) Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: insights based on FIGARO-DKD and FIDELIO-DKD. Diabetes Obes Metab. 26:924–936 [PMID: 38037539]
  26. Fu EL, Kutz A, Desai RJ (2023) Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown. Kidney Int 103(1):30–33 [PMID: 36603981]
  27. Gorriz JL, Gonzalez-Juanatey JR, Facila L, Soler MJ, Valle A, Ortiz A (2023) Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease. Nefrologia (Engl Ed) 43(4):386–398 [PMID: 37813743]
  28. Dutta D, Surana V, Bhattacharya S, Aggarwal S, Sharma M (2022) Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: a meta-analysis. Indian J Endocrinol Metab 26(3):198–205 [PMID: 36248038]
  29. Redon J (2022) New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone. Cardiovasc Res 118(5):e36–e37 [PMID: 35333317]
  30. Zhang Y, Wang J, Jiang L, Wang T, Li Z, Fu X, Huang W, Xiao Y, Wang S, Zhao J (2022) Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetol Metab Syndr 14(1):156 [PMID: 36303247]
  31. Bramlage P, Lanzinger S, Muhldorfer S, Milek K, Gillessen A, Veith R, Ohde T, Danne T, Holl RW, Seufert J (2023) An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria. Cardiovasc Diabetol 22(1):108 [PMID: 37158855]
  32. Shaikh A, Ray J, Campbell KN (2022) Role of finerenone in the treatment of diabetic kidney disease: patient selection and clinical perspectives. Ther Clin Risk Manag 18:753–760 [PMID: 35937973]
  33. Zheng Y, Ma S, Huang Q, Fang Y, Tan H, Chen Y, Li C (2022) Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease. Kidney Blood Press Res 47(4):219–228 [PMID: 35034019]
  34. Kim DL, Lee SE, Kim NH (2023) Renal protection of mineralocorticoid receptor antagonist, finerenone in diabetic kidney disease. Endocrinol Metab (Seoul) 38(1):43–55 [PMID: 36891650]
  35. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G (2019) Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol 50(5):333–344 [PMID: 31655812]
  36. Singh AK, Singh A, Singh R, Misra A (2022) Finerenone in diabetic kidney disease: a systematic review and critical appraisal. Diabetes Metab Syndr 16(10):102638 [PMID: 36223666]
  37. Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B (2019) Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol 50(5):345–356 [PMID: 31665733]
  38. Al-Kindi S, Motairek I, Janus S, Deo S, Rahman M, Neeland IJ, Rajagopalan S (2022) Time-varying cardiovascular effects of finerenone in diabetic kidney disease: insights from FIDELIO-DKD and FIGARO-DKD trials. J Am Coll Cardiol 80(19):1855–1856 [PMID: 36328698]
  39. Verma A, Patel AB (2021) Finerenone: a non-steroidal mineralocorticoid receptor blocker for diabetic kidney disease. Trends Endocrinol Metab 32(5):261–263 [PMID: 33637415]
  40. Huang T, Xu G (2018) Corrigendum to “The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: progress and challenges.” Metabolism. 82:124 [PMID: 29709221]
  41. Yu MK, Chang TI (2023) Role of finerenone in contemporary clinical care for diabetic kidney disease. Clin J Am Soc Nephrol 18(5):551–553 [PMID: 37027509]
  42. Sridhar VS, Liu H, Cherney D (2021) Finerenone-a new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease. Am J Kidney Dis 78(2):309–311 [PMID: 33753202]
  43. Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA (2015) Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs 24(8):1123–1135 [PMID: 26095025]
  44. Gilbert RE (2017) Finerenone in diabetic kidney disease -so far, so good. J Diabetes Complications 31(4):651–652 [PMID: 28153675]
  45. Marzolla V, Infante M, Armani A, Rizzo M, Caprio M (2022) Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Expert Opin Drug Saf 21(9):1161–1170 [PMID: 36174659]
  46. Filippatos G, Anker SD, August P, Coats A, Januzzi JL, Mankovsky B, Rossing P, Ruilope LM, Pitt B, Sarafidis P et al (2023) Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. Eur Heart J Cardiovasc Pharmacother 9(2):183–191 [PMID: 36639130]
  47. Filippatos G, Anker SD, Pitt B, McGuire DK, Rossing P, Ruilope LM, Butler J, Jankowska EA, Michos ED, Farmakis D et al (2022) Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease. Eur Heart J Cardiovasc Pharmacother 9(1):85–93 [PMID: 36251465]
  48. Zhang Y, Jiang L, Wang J, Wang T, Chien C, Huang W, Fu X, Xiao Y, Fu Q, Wang S et al (2022) Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol 21(1):232 [PMID: 36335326]
  49. Makembi AB, Mohamadou I, Galichon P (2021) Finerenone and chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 384(11):e42 [PMID: 33730466]
  50. Edwards NC, Ferro CJ, Townend JN (2021) Finerenone and chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 384(11):e42 [PMID: 33730467]
  51. Bakris GL, Ruilope LM, Anker SD, Filippatos G, Pitt B, Rossing P, Fried L, Roy-Chaudhury P, Sarafidis P, Ahlers C et al (2023) A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. KIDNEY INT 103(1):196–206 [PMID: 36367466]
  52. Raj R (2022) Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease. Curr Opin Nephrol Hypertens 31(3):265–271 [PMID: 35165249]
  53. Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes according to Baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD Study. Diabetes Care 45(4):888–897 [PMID: 35061867]
  54. D’Marco L, Puchades MJ, Gandia L, Forquet C, Gimenez-Civera E, Panizo N, Reque J, Juan-Garcia I, Bermudez V, Gorriz JL (2021) Finerenone: a potential treatment for patients with chronic kidney disease and type 2 diabetes mellitus. touchREV Endocrinol. 17(2):84–87 [PMID: 35118452]
  55. Green JB, Mottl AK, Bakris G, Heerspink H, Mann J, McGill JB, Nangaku M, Rossing P, Scott C, Gay A et al (2023) Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant 38(4):894–903 [PMID: 35700142]
  56. Ruilope LM, Agarwal R, Anker SD, Filippatos G, Pitt B, Rossing P, Sarafidis P, Schmieder RE, Joseph A, Rethemeier N et al (2022) Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension 79(12):2685–2695 [PMID: 36252131]
  57. Gonzalez-Juanatey JR, Gorriz JL, Ortiz A, Valle A, Soler MJ, Facila L (2023) Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med 55(1):502–513 [PMID: 36719097]
  58. Filippatos G, Anker SD, Agarwal R, Ruilope LM, Rossing P, Bakris GL, Tasto C, Joseph A, Kolkhof P, Lage A et al (2022) Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial. Circulation 145(6):437–447 [PMID: 34775784]
  59. Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Amod A, Marre M, Joseph A, Lage A et al (2022) Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial. Diabetes Obes Metab 24(1):125–134 [PMID: 34580995]
  60. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45(12):2991–2998 [PMID: 35972218]
  61. Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, Lambelet M, Lawatscheck R, Bakris GL, Ruilope LM et al (2022) Finerenone and heart failure outcomes by kidney function/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail 10(11):860–870 [PMID: 36328655]
  62. Agarwal R, Pitt B, Rossing P, Anker SD, Filippatos G, Ruilope LM, Kovesdy CP, Tuttle K, Vaduganathan M, Wanner C et al (2023) Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone. JAMA Cardiol 8(8):732–741 [PMID: 37314801]
  63. Filippatos G, Anker SD, Agarwal R, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Schloemer P, Tornus I, Joseph A et al (2021) Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation 143(6):540–552 [PMID: 33198491]
  64. Allison SJ (2021) Finerenone in chronic kidney disease. Nat Rev Nephrol 17(1):13 [PMID: 33110253]
  65. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252–2263 [PMID: 34449181]
  66. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474–484 [PMID: 35023547]
  67. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219–2229 [PMID: 33264825]
  68. Agarwal R, Anker SD, Bakris G, Filippatos G, Pitt B, Rossing P, Ruilope L, Gebel M, Kolkhof P, Nowack C et al (2022) Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant 37(6):1014–1023 [PMID: 33280027]
  69. Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, Malyszko J, Ruilope LM, Rossignol P, Rossing P et al (2023) A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J 16(2):293–302 [PMID: 36864892]
  70. Ingelfinger JR, Rosen CJ (2020) Finerenone—halting relative hyperaldosteronism in chronic kidney disease. N Engl J Med 383(23):2285–2286 [PMID: 33095527]
  71. van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T (2022) Finerenone dose-exposure-response for the primary kidney outcome in FIDELIO-DKD Phase III: population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet 61(3):439–450 [PMID: 34773606]
  72. Bao W, Zhang M, Li N, Yao Z, Sun L (2022) Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. Eur J Clin Pharmacol 78(12):1877–1887 [PMID: 36273065]
  73. Yasmin F, Aamir M, Najeeb H, Atif AR, Siddiqui AH, Ahsan MN, Moeed A, Ali SH, Tahir HM, Asghar MS (2023) Efficacy and safety of finerenone in chronic kidney disease and type 2 diabetes patients: a systematic review and meta-analysis. Ann Med Surg (Lond) 85(10):4973–4980 [PMID: 37811017]
  74. Zhu Y, Song M, Chen T, Yang Z, Liu Y (2023) Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta analysis of randomized control trials. Int Urol Nephrol 55(5):1373–1381 [PMID: 36571667]
  75. Fu Z, Geng X, Chi K, Song C, Wu D, Liu C, Hong Q (2021) Reply to letter to the editor regarding “Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis.” Ann Palliat Med 10(10):11242–11243 [PMID: 34670380]
  76. Jyotsna F, Mahfooz K, Patel T, Parshant F, Simran F, Harsha F, Neha F, Jyotishna D, Mishra D, Subedi S et al (2023) A systematic review and meta-analysis on the efficacy and safety of finerenone therapy in patients with cardiovascular and chronic kidney diseases in type 2 diabetes mellitus. Cureus 15(7):e41746 [PMID: 37575756]
  77. Zhang MZ, Bao W, Zheng QY, Wang YH, Sun LY (2022) Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. Front Pharmacol 13:819327 [PMID: 35197856]
  78. Ruilope LM, Pitt B, Anker SD, Rossing P, Kovesdy CP, Pecoits-Filho R, Pergola P, Joseph A, Lage A, Mentenich N et al (2023) Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. Nephrol Dial Transplant 38(2):372–383 [PMID: 35451488]
  79. Zhang H, Xie J, Hao C, Li X, Zhu D, Zheng H, Xu X, Mo Z, Lu W, Lu Y et al (2023) Finerenone in patients with chronic kidney disease and type 2 diabetes: the FIDELIO-DKD Subgroup from China. Kidney Dis (Basel) 9(6):498–506 [PMID: 38089437]
  80. DeFronzo RA, Bakris GL (2022) Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab 24(7):1197–1205 [PMID: 35302284]
  81. Moura-Neto JA, Ronco C (2021) Finerenone and chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 384(11):e42 [PMID: 33730469]
  82. Agarwal R, Ruilope LM, Ruiz-Hurtado G, Haller H, Schmieder RE, Anker SD, Filippatos G, Pitt B, Rossing P, Lambelet M et al (2023) Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens 41(2):295–302 [PMID: 36583355]
  83. Rossing P, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Fonseca V, Umpierrez GE, Caramori ML, Joseph A et al (2023) Finerenone in patients across the spectrum of chronic kidney disease and type 2 diabetes by glucagon-like peptide-1 receptor agonist use. Diabetes Obes Metab 25(2):407–416 [PMID: 36193847]
  84. Filippatos G, Pitt B, Agarwal R, Farmakis D, Ruilope LM, Rossing P, Bauersachs J, Mentz RJ, Kolkhof P, Scott C et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 24(6):996–1005 [PMID: 35239204]
  85. Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM, Butler J, Lam C, Kolkhof P, Roberts L et al (2021) Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol 78(2):142–152 [PMID: 34015478]
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0diseasekidneyCKDDNMRDKDDMrenaldiabeticnephropathyactionrecentprevalenceyearglobalDiabeticcombinedalsocauseend-stagereceptorplaysroleprogressionclinicalapplicationadverseFinerenonenon-steroidalMRAmechanismfinerenonetreatingreactionsprospectivetreatmentChronicdiverseetiologiescomplexpathogenesispronerecurrentepisodesprolongedillnessyearsincreasinggeneralpopulationreached143%commoncomplicationdiabetesmellitus20-40%patientsmainESRDcatalyzesapproximately30-50%casesaffectingaround285millionindividualsprimarilytriggersleadingworldwideResearchindicatesactivationmineralocorticoidonsetCounteractingoveractivationoffersantioxidativeanti-inflammatoryanti-fibroticbenefitstherebyamelioratingtargetorgandamageantagonistsMRAsspironolactoneeplerenonevalidatedprotectionHoweverhinderedeffectsincludinghyperkalemiagynecomastiamaleserectiledysfunctionmenstrualirregularitiesfemalesnovelexhibitsuniquebindinginhibitingrecruitmenttranscriptionco-factorsinvolvedgeneexpressioneffectivelyslowingadditiondemonstratesimprovedsafetyefficacyheartfailurechronicsignificantmanagementatrialfibrillationmyocardialinfarctionarticlereviewsstudiessummarizingevidencetrialsuseinhibitorsfutureaimingprovideinsightspreventionRoleAdverseMechanismMineralocorticoidantagonist

Similar Articles

Cited By